Paragonix SherpaPak: A Promising Solution to Increase Donor Heart Availability?

Paragonix Technologies Inc., a leader in organ preservation technology and research, has presented groundbreaking new data on how their Paragonix SherpaPak Cardiac Transport System can significantly improve outcomes for recipients of extended criteria donor hearts.

The study compared the use of traditional ice-cold storage to the Paragonix system, and found that those who used the latter experienced a 45% reduction in Primary Graft Dysfunction (PGD) and a 55% reduction in Severe PGD, a complication that can reduce long-term survival rates.

These impressive results demonstrate the potential of the Paragonix SherpaPak to revolutionize organ transplantation and give hope to those in need of a life-saving heart transplant.

The GUARDIAN-Heart Registry, a research project spanning nine transplant centers across the United States, collected data from 330 patients between October 2015 and January 2023. Through this study, valuable insight was gained into the state of heart transplants in the United States.

This study uncovered some fascinating findings, including that…

A remarkable difference was observed in the occurrence of Severe Primary Graft Dysfunction (PGD) among recipients of donor hearts preserved on conventional ice storage versus the Paragonix SherpaPak System – 13.9% and 6.2%, respectively (p=0.022). This finding provides compelling evidence of the superior efficacy of the Paragonix SherpaPak System in preventing PGD.

The use of the Paragonix SherpaPak system has resulted in a significant reduction in the need for post-transplant mechanical circulatory support, with a 36% reduction (p=0.012) and a 49% reduction in the newly placed ECMO/VAD post-transplant (p=0.03). These results demonstrate the efficacy of this technology in improving patient outcomes.

Paragonix SherpaPak demonstrated an impressive 92.9% 1-year survival rate in its cohort, setting a high standard of care that others in the field will strive to meet.

The results of this study have the potential to revolutionize transplant surgery, providing hope to countless patients on the waiting list. By utilizing the SherpaPak system, post-transplant complications associated with high-risk donors can be significantly reduced, thus allowing for a much wider range of extended criteria donors.

This is a major breakthrough for transplant surgeons, who are always striving for ways to safely increase access to donor hearts. Dr. Roxana Moayedifar of the Medical University of Vienna (Austria) recognizes the incredible importance of this research and its potential to change the lives of those waiting for a transplant.

Paragonix Technologies are paving the way for a new approach to life-saving heart transplants, and the results of their latest study provide strong evidence of its effectiveness. By utilizing the company’s advanced organ preservation technologies, the donor pool can be expanded to include extended criteria donors, potentially increasing the number of life-saving heart transplants. According to Dr. Lisa Anderson, CEO and President of Paragonix Technologies, this is an incredibly encouraging development that brings hope to many in need.

About Paragonix Technologies

Paragonix Technologies is revolutionizing the organ transplant industry with their innovative approach to preservation that significantly surpasses the traditional standard of care. As a leading developer, manufacturer, and service provider, they are committed to providing the best possible solutions for organ transplantation.

Paragonix Advanced Organ Preservation devices are revolutionizing the organ transplant process. Combining clinically-proven, stable cooling techniques with digital tracking and monitoring technologies, clinicians can now have complete control and oversight throughout the donor organ journey.

This cutting-edge technology has been backed up by the GUARDIAN clinical registries, the largest database of organ preservation data in the world, which has revealed positive post-transplant outcomes in transplant recipients.

Leave a Comment